Prospects for COPD treatment

Maria Gabriella Matera; Mario Cazzola; Clive Page

doi:10.1016/j.coph.2020.11.003

Prospects for COPD treatment

Maria Gabriella Matera, Mario Cazzola^*, Clive Page

^*Corresponding author for this work

Institute of Pharmaceutical Science

Research output: Contribution to journal › Review article › peer-review

48 Citations (Scopus)

Abstract

The management of chronic obstructive pulmonary disease (COPD) is fundamentally still heavily dependent on the use of bronchodilators and corticosteroids. Therefore, there is a need for alternative, more effective and safer therapeutic approaches. In particular, since inflammation in COPD lungs is often poorly responsive to corticosteroid treatment, novel pharmacological anti-inflammatory approaches are needed to optimally treat COPD patients. There have been multiple attempts to develop drugs that inhibit recruitment and activation of inflammatory cells, such as macrophages, neutrophils and T-lymphocytes, in the lungs of patients with COPD or target inflammatory mediators that are important in the recruitment or activation of these inflammatory cells or released by such cells. This review article focuses on novel classes of anti-inflammatory drugs that have already been tested in humans as possible treatments for patients with COPD.

Original language	English
Pages (from-to)	74-84
Number of pages	11
Journal	Current Opinion in Pharmacology
Volume	56
DOIs	https://doi.org/10.1016/j.coph.2020.11.003
Publication status	Published - Feb 2021

Keywords

Anti-inflammatory treatment
COPD
New therapies

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.coph.2020.11.003

Cite this

@article{356d14b46e564dcba894be00e963639b,

title = "Prospects for COPD treatment",

abstract = "The management of chronic obstructive pulmonary disease (COPD) is fundamentally still heavily dependent on the use of bronchodilators and corticosteroids. Therefore, there is a need for alternative, more effective and safer therapeutic approaches. In particular, since inflammation in COPD lungs is often poorly responsive to corticosteroid treatment, novel pharmacological anti-inflammatory approaches are needed to optimally treat COPD patients. There have been multiple attempts to develop drugs that inhibit recruitment and activation of inflammatory cells, such as macrophages, neutrophils and T-lymphocytes, in the lungs of patients with COPD or target inflammatory mediators that are important in the recruitment or activation of these inflammatory cells or released by such cells. This review article focuses on novel classes of anti-inflammatory drugs that have already been tested in humans as possible treatments for patients with COPD.",

keywords = "Anti-inflammatory treatment, COPD, New therapies",

author = "Matera, {Maria Gabriella} and Mario Cazzola and Clive Page",

year = "2021",

month = feb,

doi = "10.1016/j.coph.2020.11.003",

language = "English",

volume = "56",

pages = "74--84",

journal = "Current Opinion in Pharmacology",

issn = "1471-4892",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Prospects for COPD treatment

AU - Matera, Maria Gabriella

AU - Cazzola, Mario

AU - Page, Clive

PY - 2021/2

Y1 - 2021/2

N2 - The management of chronic obstructive pulmonary disease (COPD) is fundamentally still heavily dependent on the use of bronchodilators and corticosteroids. Therefore, there is a need for alternative, more effective and safer therapeutic approaches. In particular, since inflammation in COPD lungs is often poorly responsive to corticosteroid treatment, novel pharmacological anti-inflammatory approaches are needed to optimally treat COPD patients. There have been multiple attempts to develop drugs that inhibit recruitment and activation of inflammatory cells, such as macrophages, neutrophils and T-lymphocytes, in the lungs of patients with COPD or target inflammatory mediators that are important in the recruitment or activation of these inflammatory cells or released by such cells. This review article focuses on novel classes of anti-inflammatory drugs that have already been tested in humans as possible treatments for patients with COPD.

AB - The management of chronic obstructive pulmonary disease (COPD) is fundamentally still heavily dependent on the use of bronchodilators and corticosteroids. Therefore, there is a need for alternative, more effective and safer therapeutic approaches. In particular, since inflammation in COPD lungs is often poorly responsive to corticosteroid treatment, novel pharmacological anti-inflammatory approaches are needed to optimally treat COPD patients. There have been multiple attempts to develop drugs that inhibit recruitment and activation of inflammatory cells, such as macrophages, neutrophils and T-lymphocytes, in the lungs of patients with COPD or target inflammatory mediators that are important in the recruitment or activation of these inflammatory cells or released by such cells. This review article focuses on novel classes of anti-inflammatory drugs that have already been tested in humans as possible treatments for patients with COPD.

KW - Anti-inflammatory treatment

KW - COPD

KW - New therapies

UR - http://www.scopus.com/inward/record.url?scp=85097747963&partnerID=8YFLogxK

U2 - 10.1016/j.coph.2020.11.003

DO - 10.1016/j.coph.2020.11.003

M3 - Review article

C2 - 33333428

AN - SCOPUS:85097747963

SN - 1471-4892

VL - 56

SP - 74

EP - 84

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

ER -

Prospects for COPD treatment

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this